Eurobio Scientific Team
Financial Statements
Eurobio Scientific has been listed on Euronext Growth Paris (ALERS) since 2005.
2024
(in French)
2023
(in French)
2022
(in French)
2021
(in French)
Press releases
Press releases
- FY 2025 revenue
- Replacement of a Statutory Auditor
- Results for the first semester of fiscal year 2025
- Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy
- Resultat Annuel 2024 – Growth of core business and strategic execution
- Eurobio Scientific increases its footprint in Italy
- Termination of the liquidity contract
- Calendar of financial publications 2025
- Eurobio Scientific: successful takeover bid at the end of its first period, reopening of the offer from 4 to 17 December
- Opening of the public purchase offer until November 27
- Eurobio Scientific: lifting of the last regulatory suspensive condition to the takeover bid project initiated by EB Development
- Results for the first half of 2024
- Eurobio Scientific completes acquisition of Endopredict® genomic test from Myriad Genetics
- Suspension of the liquidity contract
- First half 2024, a solid start of the financial year in an uncertain environment – PROPOSED TENDER OFFER
- Agreement to acquire the ENDOPREDICT gene expression test for breast cancer
- Publication of the 2023 financial annual report
- 2023 annual results, growth in Core Business and strategic deployment
- 2023 Annuel revenue at 130,1 MEUR
- Capital reduction through cancellation of treasury shares-2024
- Catherine Courboillet to join the Board as an Independant Member
- Availability of the 2023 half-yearly financial report
- GenDx reduces organ matching time to 3 hours
- H1 2023 Results: Solid performance of Core Business and acceleration of strategic deployment
- Acceleration of strategic deployment in the first half of 2023
- Capital reduction through cancellation of treasury shares
- All resolutions approved at the 2023 Annual General Meeting – The Board of Directors appoints a new governance
- Acquisition of D.I.D. in Italy
- First IVDR CE marking of PCR tests
- Publication of the 2022 annual financial report
- 2022 annual results : very strong performance and strengthening of the Core Business
- Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific
- Eurobio Scientific formalises the appointment of Anne-Sophie Herelle as Group CFO
- 2022 annual turnover of €152.5M
- H2 2022 report on the liquidity contract
- Exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
- Half-year financial report available
- H1 2022 Results: continued growth of non-COVID activity
- Eurobio Scientific finalizes the acquisition of GenDx, international HLA diagnostics specialist
- Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist
- First half turnover of €83.6 million maintained at a high level
- Half-year report on liquidity contract
- Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox
- Eurobio Scientific’s annual shareholders’ meeting
- Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV
- Closing of the Strategic Partnership with NEXTSTAGE AM
- Availability of the 2021 annual financial report
- Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility
- CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
- Maintaining high level results in 2021
- New priority test for the detection of Omicron BA.x, BA.2 and Delta of SARS-CoV-2
- Strategic partnership with NextStage AM
- 2021 TURNOVER : Exceptional level of €184.1million
- Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France
- Eurobio Scientific confirms its eligibility to the pea-pme system
